Advertisement

Targeted Oncology

, Volume 4, Issue 1, pp 37–44 | Cite as

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer

  • Chia-Chi Lin
  • Chih-Hsin YangEmail author
Review

Abstract

Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC. Several phase II trials have been conducted utilizing EGFR TKIs in elderly or poor performance status patients with advanced NSCLC. This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC.

Keywords

Epidermal growth factor receptor Erlotinib Gefitinib Non-small cell lung cancer Tyrosine kinase inhibitor 

Notes

Conflict of interest statement

Chia-Chi Lin, none declared. Chih-Hsin Yang had received honoraria from Astra-Zeneca and Roche.

References

  1. 1.
    Kelly K, Crowley J, Bunn PA Jr., Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non—small-cell lung cancer: a southwest oncology group trial. J Clin Oncol 19:3210–3218PubMedGoogle Scholar
  2. 2.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92–98CrossRefPubMedGoogle Scholar
  3. 3.
    Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024CrossRefPubMedGoogle Scholar
  4. 4.
    Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMedGoogle Scholar
  5. 5.
    Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 366:1527–1537CrossRefPubMedGoogle Scholar
  6. 6.
    Yang CH (2008) EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 60(2):S23–S30CrossRefPubMedGoogle Scholar
  7. 7.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  8. 8.
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMedGoogle Scholar
  9. 9.
    Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311CrossRefPubMedGoogle Scholar
  10. 10.
    Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26:2745–2753CrossRefPubMedGoogle Scholar
  11. 11.
    Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N, Thatcher N (2006) Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1:847–855CrossRefPubMedGoogle Scholar
  12. 12.
    Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CK, Sellers MV, Lowe ES, Sun Y, Liao ML, Oserlind K, Reck R, Armour AA, Sheperd FA, Lippman SM, Douillard JY (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372:1809–1818CrossRefPubMedGoogle Scholar
  13. 13.
    Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26:4244–4252CrossRefPubMedGoogle Scholar
  14. 14.
    Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American society of clinical oncology treatment of unresectable non-smallcell lung cancer guideline: update 2003. J Clin Oncol 22:330–353CrossRefPubMedGoogle Scholar
  15. 15.
    Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le CT, Manegold C, Perrone F, Rosell R, Shepherd F, De Petris L, Di Maio M, Langer C (2005) Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23:3125–3137CrossRefPubMedGoogle Scholar
  16. 16.
    The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72CrossRefGoogle Scholar
  17. 17.
    Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena M (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-smallcell lung cancer. J Clin Oncol 18:2529–2536PubMedGoogle Scholar
  18. 18.
    Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372PubMedGoogle Scholar
  19. 19.
    Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan thoracic oncology group trial (WJTOG 9904). J Clin Oncol 24:3657–3663CrossRefPubMedGoogle Scholar
  20. 20.
    Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 94:173–181PubMedGoogle Scholar
  21. 21.
    Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR (2006) Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest oncology group (S0027). J Thorac Oncol 1:537–544CrossRefPubMedGoogle Scholar
  22. 22.
    Langer CJ, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH (2007) Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern cooperative oncology group performance status 2 non-small cell lung cancer patients: ECOG 1599. J Clin Oncol 25:418–423CrossRefPubMedGoogle Scholar
  23. 23.
    Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati SF, Filipazzi V, Lorusso V, Carrozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F (2007) Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25:4663–4669CrossRefPubMedGoogle Scholar
  24. 24.
    Gridelli C, Maione P, Castaldo V, Rossi A (2003) Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 89:1827–1829CrossRefPubMedGoogle Scholar
  25. 25.
    Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crino L (2004) Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 90:82–86CrossRefPubMedGoogle Scholar
  26. 26.
    Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Tanimoto M (2005) Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama lung cancer study group experience. Acta Oncol 44:717–722CrossRefPubMedGoogle Scholar
  27. 27.
    Bearz A, Fratino L, Spazzapan S, Berretta M, Giacalone A, Simonelli C, Tirelli U (2007) Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 55:125–127CrossRefPubMedGoogle Scholar
  28. 28.
    Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsao CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang WC, Kuo HP, Yu CT, Lin ZZ, Kao WY (2008) High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 62:78–84CrossRefPubMedGoogle Scholar
  29. 29.
    Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y (2008) A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 3:1166–1171CrossRefPubMedGoogle Scholar
  30. 30.
    Crino L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26:4253–4260CrossRefPubMedGoogle Scholar
  31. 31.
    Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Janne PA (2007) Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760–766CrossRefPubMedGoogle Scholar
  32. 32.
    Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr., Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655PubMedCrossRefGoogle Scholar
  33. 33.
    Scagliotti G, Rossi A, Novello S, De Marinis F, Dogliotti L, Crino L, Lorusso V, Martoni A, Paccagnella A, Gridelli C (2004) Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7081Google Scholar
  34. 34.
    Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G (2008) Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 112:2021–2029CrossRefPubMedGoogle Scholar
  35. 35.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 22:777–784CrossRefPubMedGoogle Scholar
  36. 36.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 22:785–794CrossRefPubMedGoogle Scholar
  37. 37.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller V (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899CrossRefPubMedGoogle Scholar
  38. 38.
    Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De RF, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, von Pawel J (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552CrossRefPubMedGoogle Scholar
  39. 39.
    Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, van Zandwijk N, Di Maio M, Martelli O, De Marinis F (2004) Treatment of advanced non-smallcell lung cancer patients with ECOG performance status 2: results of an European experts panel. Ann Oncol 15:419–426CrossRefPubMedGoogle Scholar
  40. 40.
    Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074–1080CrossRefPubMedGoogle Scholar
  41. 41.
    Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham TN, Olivares R, Berille J (2000) A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145–157CrossRefPubMedGoogle Scholar
  42. 42.
    Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83:447–453Google Scholar
  43. 43.
    Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR (2005) Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23:190–196CrossRefPubMedGoogle Scholar
  44. 44.
    Su WP, Yang CH, Yu CJ, Shih JY, Hsu C, Yang PC (2005) Gefitinib treatment for non-small cell lung cancer—a study including patients with poor performance status. J Formos Med Assoc 104:557–562PubMedGoogle Scholar
  45. 45.
    Chang GC, Chen KC, Yang TY, Yin MC, Lin CP, Kuo BI, Hsu JY (2005) Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest New Drugs 23:73–77CrossRefPubMedGoogle Scholar
  46. 46.
    Hotta K, Inoue A, Kiura K, Ueoka H, Nukiwa T, Tanimoto M (2005) Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. Lung Cancer 50:413–415CrossRefPubMedGoogle Scholar
  47. 47.
    Chang GC, Tsai CM, Chen KC, Yu CJ, Shih JY, Yang TY, Lin CP, Hsu JY, Chiu CH, Perng RP, Yang PC, Yang CH (2006) Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol 1:520–525CrossRefPubMedGoogle Scholar
  48. 48.
    Lee DH, Han JY, Kim HT, Lee JS (2006) Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer 53:339–345CrossRefPubMedGoogle Scholar
  49. 49.
    Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC (2006) Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced non-small cell lung cancer. Cancer 107:1873–1882CrossRefPubMedGoogle Scholar
  50. 50.
    Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, Thomas M, Jones SF, Dickson NR, Scullin DC, Bradof JE, Rubinsak JR, Brierre JE, Greco FA (2005) Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a minnie pearl cancer research network phase II Trial. Clin Lung Cancer 7:127–132CrossRefPubMedGoogle Scholar
  51. 51.
    Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR (2008) Southwest oncology group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 3:1026–1031CrossRefPubMedGoogle Scholar
  52. 52.
    Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D (2008) Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2. J Clin Oncol 26:863–869CrossRefPubMedGoogle Scholar
  53. 53.
    Yang CH, Shih J, Chao T, Tsai C, Yu C, Yang P, Streit M, Shahidi M, Miller VA (2008) Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm phase II clinical trial. J Clin Oncol (Meeting Abstracts) 26:8026Google Scholar
  54. 54.
    Janne PA, von PJ, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD (2007) Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small cell lung cancer. J Clin Oncol 25:3936–3944CrossRefPubMedGoogle Scholar
  55. 55.
    Janne PA, Schellens JH, Engelman JA, Eckhardt SG, Millham R, Denis LJ, Britten CD, Wong SG, Boss DS, Camidge DR (2008) Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol (Meeting Abstracts) 26:8027Google Scholar
  56. 56.
    Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64:3958–3965CrossRefPubMedGoogle Scholar
  57. 57.
    Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665–7670CrossRefPubMedGoogle Scholar
  58. 58.
    Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, Rowinsky EK (2006) Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24:2252–2260CrossRefPubMedGoogle Scholar
  59. 59.
    Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M (2006) EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 51:363–368CrossRefPubMedGoogle Scholar
  60. 60.
    Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small cell lung cancer. J Clin Oncol 25:4270–4277CrossRefPubMedGoogle Scholar
  61. 61.
    Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Costa D, Vrindavanam N, Yanagihara R, Pennell N, Lynch TJ (2008) Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. J Clin Oncol (Meeting Abstracts) 26:8028Google Scholar
  62. 62.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64:4931–4941CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of OncologyNational Taiwan University HospitalTaipeiTaiwan

Personalised recommendations